197 related articles for article (PubMed ID: 28335434)
1. Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Jandial DD; Krill LS; Chen L; Wu C; Ke Y; Xie J; Hoang BH; Zi X
Molecules; 2017 Mar; 22(3):. PubMed ID: 28335434
[TBL] [Abstract][Full Text] [Related]
2. Flavokawain A induces apoptosis in MCF-7 and MDA-MB231 and inhibits the metastatic process in vitro.
Abu N; Akhtar MN; Yeap SK; Lim KL; Ho WY; Zulfadli AJ; Omar AR; Sulaiman MR; Abdullah MP; Alitheen NB
PLoS One; 2014; 9(10):e105244. PubMed ID: 25286005
[TBL] [Abstract][Full Text] [Related]
3. Flavokawain A inhibits prostate cancer cells by inducing cell cycle arrest and cell apoptosis and regulating the glutamine metabolism pathway.
Wang K; Zhang W; Wang Z; Gao M; Wang X; Han W; Zhang N; Xu X
J Pharm Biomed Anal; 2020 Jul; 186():113288. PubMed ID: 32361091
[TBL] [Abstract][Full Text] [Related]
4. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
5. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
6. FOXO1A is a target for HER2-overexpressing breast tumors.
Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
8. Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.
Liu Z; Xu X; Li X; Liu S; Simoneau AR; He F; Wu XR; Zi X
Cancer Prev Res (Phila); 2013 Dec; 6(12):1365-75. PubMed ID: 24121102
[TBL] [Abstract][Full Text] [Related]
9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
Gupta P; Srivastava SK
BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
[TBL] [Abstract][Full Text] [Related]
11. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.
Tang Y; Simoneau AR; Xie J; Shahandeh B; Zi X
Cancer Prev Res (Phila); 2008 Nov; 1(6):439-51. PubMed ID: 19138991
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
14. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
15. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
19. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]